Reviewing CardioGenics (OTCMKTS:CGNH) & Sight Sciences (NASDAQ:SGHT)

Sight Sciences (NASDAQ:SGHT) and CardioGenics (OTCMKTS:CGNH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Institutional & Insider Ownership

55.5% of Sight Sciences shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by insiders. Comparatively, 41.4% of CardioGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sight Sciences and CardioGenics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1	3	4	0	2.38
CardioGenics	0	0	0	0	0.00

Sight Sciences presently has a consensus target price of $8.30, indicating a potential upside of 11.56%. Given Sight Sciences’ stronger consensus rating and higher possible upside, analysts plainly believe Sight Sciences is more favorable than CardioGenics.

Volatility & Risk

Sight Sciences has a beta of 2.42, suggesting that its share price is 142% more volatile than the S&P 500. Comparatively, CardioGenics has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sight Sciences and CardioGenics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$79.87 million	4.92	-$51.51 million	($0.90)	-8.27
CardioGenics	N/A	N/A	N/A	N/A	N/A

CardioGenics has lower revenue, but higher earnings than Sight Sciences.

Profitability

This table compares Sight Sciences and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-60.63%	-61.59%	-36.11%
CardioGenics	N/A	N/A	N/A

About Sight Sciences

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.